ABSTRACT
This chapter presents a survival analysis of stage one and two lung cancer patients enroled in three clinical trials of adjuvant specific active tumour associated antigen (TAA) immunotherapy. The meta analysis is restricted to completely immunized patients who received the full course of immunization in comparison with the corresponding non immunized control group. A total of 41 stages one and two lung cancer patients from Eastern Ontario and Western Quebec were randomly allocated to three treatment arms: 17 patients received intradermally soluble TAA well homogenized in Freund's complete adjuvant once per month for 3 months; 14 patients received methotrexate in addition to TAA immunotherapy and 10 patients received methotrexate alone. Specific immunotherapy with TAA has been shown to be highly effective in improving the survival probability of stage one and two lung cancer patients. All the three clinical trials considered show a consistent survival advantage in favour of the immunized.
